A Pituitary Society update to acromegaly management guidelines

Maria Fleseriu, Beverly M.K. Biller, Pamela U. Freda, Monica R. Gadelha, Andrea Giustina, Laurence Katznelson, Mark E. Molitch, Susan L. Samson, Christian J. Strasburger, A. J. van der Lely, Shlomo Melmed*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

115 Scopus citations


Guidelines and consensus statements ensure that physicians managing acromegaly patients have access to current information on evidence-based treatments to optimize outcomes. Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Consensus Group statements. This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
Issue number1
StatePublished - Feb 2021


  • Acromegaly
  • Growth hormone
  • Insulin-like growth factor I
  • Oral octreotide
  • Pegvisomant
  • Pituitary adenoma
  • Somatostatin receptor ligand

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'A Pituitary Society update to acromegaly management guidelines'. Together they form a unique fingerprint.

Cite this